GlassScriptPhysician profile
Terri W Jerkins
NPI 1538147319
$567,245.73
in general payments reported to CMS, 2019-2025
59 companies · $73K in 2025
The $73K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133K · 2020: $89K · 2021: $105K · 2022: $109K · 2023: $24K · 2024: $33K · 2025: $73K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $102K · Food and Beverage: $13K · Honoraria: $7,520 · Travel and Lodging: $6,310 · Consulting Fee: $600 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $102,170.44 |
| Food and Beverage | $13,370.81 |
| Honoraria | $7,520.00 |
| Travel and Lodging | $6,309.98 |
| Consulting Fee | $600.00 |
| Education | $112.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $355,148.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $85,532.28 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $51,310.25 | 2019-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $35,688.99 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $21,742.59 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,126.58 | 2019-2022 | |
| Abbott Laboratories | $1,675.61 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $1,431.03 | 2019-2025 | Repatha, Tepezza, Repatha |
| Insulet Corporation | $1,145.04 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $1,103.48 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $995.07 | 2019-2025 | |
| Lilly USA, LLC | $992.68 | 2020-2025 | Jardiance, Zepbound, Lyumjev |
| Abbvie INC. | $905.54 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $884.18 | 2019-2025 | |
| Dexcom, INC. | $625.23 | 2020-2025 | Dexcom G6 Transmitter |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $619.63 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Mannkind Corporation | $443.04 | 2019-2025 | Afrezza |
| Recordati_rare_diseases_inc. | $415.15 | 2021-2025 | Isturisa, Signifor Lar |
| Tandem Diabetes Care, INC. | $400.60 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astellas Pharma US INC | $292.78 | 2023-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.28 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $286.27 | 2020-2021 | |
| Ascensia Diabetes Care US INC. | $263.23 | 2022-2023 | |
| Radius Health, INC. | $241.38 | 2019-2023 | Tymlos |
| Horizon Therapeutics Plc | $223.61 | 2021-2023 | Tepezza |
| Cequr Corporation | $215.78 | 2023-2024 | Cequr Simplicity |
| Esperion Therapeutics, INC. | $206.07 | 2020-2023 | Nexletol |
| Neurocrine Biosciences, INC. | $183.69 | 2024-2025 | |
| Sequel Med Tech, LLC | $171.76 | 2025 | Twiist |
| Merck Sharp & Dohme LLC | $167.65 | 2019-2021 | |
| Antares Pharma, INC. | $162.23 | 2020-2022 | |
| Pfizer INC. | $158.61 | 2021-2024 | |
| Medtronic, INC. | $148.99 | 2023-2025 | Minimed 780g |
| Nestle Healthcare Nutrition INC. | $95.30 | 2020-2021 | |
| Ascendis Pharma Endocrinology INC | $82.47 | 2025 | Yorvipath |
| Medtronic Minimed, INC. | $75.10 | 2019 | |
| Lifescan, INC. | $71.19 | 2019-2022 | |
| Clarus Therapeutics INC. | $67.49 | 2021 | |
| Madrigal Pharmaceuticals | $64.03 | 2025 | Rezdiffra |
| Shire North American Group INC | $61.69 | 2019 | |
| Eisai INC. | $55.99 | 2019 | |
| Chiesi USA, INC. | $53.02 | 2025 | Mycapssa |
| Evoke Pharma, INC. | $49.45 | 2023-2024 | Gimoti |
| Amphastar Pharmaceuticals, INC. | $43.17 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $36.85 | 2020-2021 | |
| Kyowa Kirin, INC. | $35.07 | 2023-2024 | Crysvita |
| Biohaven Pharmaceutical Holding Company LTD. | $32.71 | 2022 | |
| Nevro Corp. | $31.40 | 2022 | |
| Companion Medical, INC. | $27.86 | 2020 | |
| Alexion Pharmaceuticals, INC. | $25.60 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $22.69 | 2021 | |
| Amryt Pharma Holdings LTD | $21.54 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.67 | 2019 | |
| Glaxosmithkline, LLC. | $17.76 | 2025 | Shingrix, Arexvy |
| Acella Pharmaceuticals, LLC | $17.39 | 2025 | NP Thyroid 60 |
| Ultragenyx Pharmaceutical INC. | $17.10 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.32 | 2023 | Quviviq |
| Amneal Pharmaceuticals LLC | $12.01 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Jerkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.